Alaunos Therapeutics, Inc. Enters Settlement Agreement with MD Anderson

Alaunos Therapeutics, Inc. has entered into a Settlement and Release Agreement with The University of Texas M.D. Anderson Cancer Center to resolve disputes regarding unpaid invoices totaling $285,055.68 under a 2019 Research and Development Agreement. The company will pay the settlement amount in installments through May 30, 2026. The agreement includes mutual releases of claims related to the unpaid invoices, with exceptions for breaches of the settlement agreement and ongoing matters like Protocol 2006-0676. This settlement aims to fully resolve all disputes stemming from the outstanding payments.